References
- Everett JR. Academic drug discovery: current status and prospects. Expert Opin Drug Discov. 2015;10(9):937–944.
- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
- Slusher BS, Conn PJ, Frye S, et al. Bringing together the academic drug discovery community. Nat Rev Drug Discov. 2013;12(11):811–812.
- Hendriks HR, Govaerts A-S, Fichtner I, et al. Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative. Br J Cancer. 2017;117:195–202.
- Karawajczyk A, Orrling KM, de Vlieger JSB, et al. The European lead factory: A blueprint for public–private partnerships in early drug discovery. Front Med. 2017;3:75.
- Shanks E, Ketteler R, Ebner D. Academic drug discovery within the United Kingdom: a reassessment. Nat Rev Drug Discov. 2015;14(7):510–514.
- Tralau-Stewart C, Low CMR, Marlin N. UK academic drug discovery. Nat Rev Drug Discov. 2014;13:15–16.
- Jordan AM, Waddell ID, Ogilvie DJ. Rethinking ‘academic’ drug discovery: the Manchester Institute perspective. Drug Discov Today. 2015;20(5):525–535.
- Neidle S. Cancer drug design and discovery. 2nd ed. New York, USA: Academic Press; 2013. p. 640.
- Matter A. Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biol Med. 2015;12:316–327.
- Nicolaou KC. The chemistry-biology-medicine continuum and the drug discovery and development process in academia. Chem Biol. 2014;21(9):1039–1045.
- Palmer M, Chaguturu R. Academia–pharma partnerships for novel drug discovery: essential or nice to have? Expert Opin Drug Discov. 2017;12(6):537–540.
- Dahlin JL, Inglese J, Walters MA. Mitigating risk in academic preclinical drug discovery. Nat Rev Drug Discov. 2015;14(4):279–294.
- Huber MA, Kraut N. Key drivers of biomedical innovation in cancer drug discovery. EMBO Mol Med. 2015;7(1):12–16.